# RxSight, Inc.: overview

RXST · Nasdaq · CIK 1111485 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rxst.md) · [Financials](/companies/rxst/financials.md) · [Filings](/companies/rxst/filings.md) · [Insiders](/companies/rxst/insiders.md)

Latest reported revenue: [$27.2m](/filings/0001193125-26-335153.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335153).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [35.3](/filings/0001193125-25-266986.md) | [40.2 d](/filings/0001193125-26-071775.md) | [37.9](/filings/0001193125-26-208921.md) | [33.6](/filings/0001193125-26-335153.md) | [30.3](/filings/0001193125-25-266986.md) | [32.6 d](/filings/0001193125-26-071775.md) | [30.9](/filings/0001193125-26-208921.md) | [27.2](/filings/0001193125-26-335153.md) |
| Gross margin | % | [71.4%](/filings/0001193125-25-266986.md) | [71.6% d](/filings/0001193125-26-071775.md) | [74.8%](/filings/0001193125-26-208921.md) | [74.9%](/filings/0000950170-25-105070.md) | [79.9%](/filings/0001193125-25-266986.md) | [77.5% d](/filings/0001193125-26-071775.md) | [76.1%](/filings/0001193125-26-208921.md) | not reported |
| Operating margin | % | [(26.1%)](/filings/0001193125-25-266986.md) | [(21.5%) d](/filings/0001193125-26-071775.md) | [(28.2%)](/filings/0001193125-26-208921.md) | [(41.6%)](/filings/0001193125-26-335153.md) | [(40.1%)](/filings/0001193125-25-266986.md) | [(34.8%) d](/filings/0001193125-26-071775.md) | [(57.7%)](/filings/0001193125-26-208921.md) | [(50.5%)](/filings/0001193125-26-335153.md) |
| Net margin | % | [(17.9%)](/filings/0001193125-25-266986.md) | [(14.8%) d](/filings/0001193125-26-071775.md) | [(21.6%)](/filings/0001193125-26-335153.md) | [(35.0%)](/filings/0001193125-26-335153.md) | [(32.4%)](/filings/0001193125-25-266986.md) | [(28.1%) d](/filings/0001193125-26-071775.md) | [(51.4%)](/filings/0001193125-26-335153.md) | [(44.4%)](/filings/0001193125-26-335153.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0001193125-25-266986.md) | not reported | [(0.20)](/filings/0001193125-26-208921.md) | [(0.29)](/filings/0001193125-26-335153.md) | [(0.24)](/filings/0001193125-25-266986.md) | not reported | [(0.38)](/filings/0001193125-26-208921.md) | [(0.29)](/filings/0001193125-26-335153.md) |
| Free cash flow | $m | [(0.5) d](/filings/0001193125-25-266986.md) | [(5.1) d](/filings/0001193125-26-071775.md) | [(9.4)](/filings/0001193125-26-208921.md) | [(5.9) d](/filings/0001193125-26-335153.md) | [(1.8) d](/filings/0001193125-25-266986.md) | [(2.3) d](/filings/0001193125-26-071775.md) | [(11.7)](/filings/0001193125-26-208921.md) | [(11.5) d](/filings/0001193125-26-335153.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [22.6](/filings/0000950170-23-006237.md) | [49.0](/filings/0000950170-25-026681.md) | [89.1](/filings/0001193125-26-071775.md) | [140](/filings/0001193125-26-071775.md) | [134](/filings/0001193125-26-071775.md) |
| Gross margin | % | [20.0%](/filings/0000950170-23-006237.md) | [43.5%](/filings/0000950170-25-026681.md) | [60.4%](/filings/0001193125-26-071775.md) | [70.7%](/filings/0001193125-26-071775.md) | [76.6%](/filings/0001193125-26-071775.md) |
| Operating margin | % | [(233.6%)](/filings/0000950170-23-006237.md) | [(129.2%)](/filings/0000950170-25-026681.md) | [(56.2%)](/filings/0001193125-26-071775.md) | [(26.3%)](/filings/0001193125-26-071775.md) | [(35.8%)](/filings/0001193125-26-071775.md) |
| Net margin | % | [(215.5%)](/filings/0000950170-23-006237.md) | [(136.2%)](/filings/0000950170-25-026681.md) | [(54.6%)](/filings/0001193125-26-071775.md) | [(19.6%)](/filings/0001193125-26-071775.md) | [(29.0%)](/filings/0001193125-26-071775.md) |
| Diluted EPS | $ per share | [(3.57)](/filings/0000950170-23-006237.md) | [(2.41)](/filings/0000950170-25-026681.md) | [(1.41)](/filings/0001193125-26-071775.md) | [(0.71)](/filings/0001193125-26-071775.md) | [(0.95)](/filings/0001193125-26-071775.md) |
| Free cash flow | $m | [(46.6)](/filings/0000950170-23-006237.md) | [(61.2)](/filings/0000950170-25-026681.md) | [(46.4)](/filings/0001193125-26-071775.md) | [(22.4)](/filings/0001193125-26-071775.md) | [(19.3)](/filings/0001193125-26-071775.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rxst/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $27.9m | 5,790,408 |  | Added +2,603,316 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $14.6m | 3,030,287 |  | Added +970,828 |
| [No Street GP LP](/funds/1765774.md) | 2026-06-30 | $9.9m | 2,055,000 |  | Added +55,000 |
| [NOMURA HOLDINGS INC](/funds/1163653.md) | 2026-06-30 | $9.6m | 2,000,060 |  | Unchanged |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $9.6m | 1,985,215 |  | Added +25,483 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.1m | 1,675,582 |  | Reduced −17,353 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $7.4m | 1,533,826 |  | Added +897,697 |
| [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $5.8m | 1,201,195 |  | Added +120,483 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $5.5m | 1,147,048 |  | Reduced −153,212 |
| [HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND](/funds/1535845.md) | 2026-06-30 | $5.5m | 1,131,400 |  | Unchanged |

## Recent filings

[All 464 filings](/companies/rxst/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:15 ET | [10-Q](/filings/0001193125-26-335153.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335153 |
| 2026-08-05 | 16:15 ET | [8-K](/filings/0001193125-26-335150.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335150 |
| 2026-07-15 | 16:23 ET | [8-K](/filings/0001193125-26-304812.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-304812 |
| 2026-07-06 | 16:15 ET | [8-K](/filings/0001193125-26-296201.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-296201 |
| 2026-07-06 | 16:15 ET | [8-K](/filings/0001193125-26-296200.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-296200 |
| 2026-06-16 | 16:30 ET | [8-K](/filings/0001193125-26-272688.md) | 5.07 Shareholder vote results | 0001193125-26-272688 |
| 2026-05-06 | 16:05 ET | [10-Q](/filings/0001193125-26-208921.md) | Quarterly report, period 2026-03-31 | 0001193125-26-208921 |
| 2026-05-06 | 16:04 ET | [8-K](/filings/0001193125-26-208912.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208912 |
| 2026-04-28 | 16:30 ET | [DEF 14A](/filings/0001193125-26-187240.md) | Proxy statement, period 2026-04-27 | 0001193125-26-187240 |
| 2026-03-19 | 16:06 ET | [8-K/A](/filings/0001193125-26-115965.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-115965 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-071775.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1c57b6be-fedc-425d-915b-bcb13a5f5dc3)

## About the filer

- CIK: 1111485
- Tickers: RXST
- Exchange: Nasdaq
- SIC code: 3851 Ophthalmic Goods
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:29 ET. No prices; not investment advice.